Report of Foreign Issuer (6-k)
May 08 2020 - 4:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of May 2020
Commission File Number: 001-37643
KITOV PHARMA LTD.
(Translation of registrant’s name into
English)
One Azrieli Center, Round Tower, Tel Aviv
6701101, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the Registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the Registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Kitov Pharma Ltd. (the “Company”
or the “Registrant”) is announcing that on May 8, 2020, the Company issued a press release, “Kitov Closes
$10.0 Million Registered Direct Offering”, which is attached hereto as Exhibit 99.1.
This Form 6-K shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be any sale of ADSs or warrants in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
This Form 6-K, including all exhibits attached
hereto, is hereby incorporated by reference into each of the Registrant’s Registration
Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117
and 333-211477), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on
May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities
and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on
Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195),
the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration
file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission
on September 16, 2019 (Registration file number 333-233795) and the Registrant’s Registration Statement on Form F-3 filed
with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333- 333-235327), to be a part
thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
May 8, 2020
|
KITOV PHARMA LTD.
|
|
|
|
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
Chief Executive Officer
|
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024